Postmenopausal hormone therapy and the risk of venous thromboembolism

Climacteric

Volumn 11, Issue 4, 2008, Pages 273-279

  Rachon, D ^a,b   Teede, H ^a,c  

^a MONASH UNIVERSITY   (Australia)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c MONASH MEDICAL CENTRE   (Australia)

Author keywords

Estrogens; Hormone replacement therapy; Menopause; Progestogens; Venous thromboembolism; Women's health

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 5 LEIDEN; CONJUGATED ESTROGEN; CYPROTERONE; DYDROGESTERONE; ESTRADIOL; ESTROGEN; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEDROXYPROGESTERONE ACETATE; NOMEGESTROL; NORETHISTERONE; NORETHISTERONE ACETATE; PLACEBO; PROGESTERONE; PROGESTERONE DERIVATIVE; PROMEGESTONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TIBOLONE;

AGE DISTRIBUTION; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG USE; HEALTH PRACTITIONER; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; MENOPAUSAL SYNDROME; MONOTHERAPY; OBESITY; PATHOGENESIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; VENOUS THROMBOEMBOLISM; WOMEN'S HEALTH;

AGE FACTORS; BODY MASS INDEX; CONTRACEPTIVE AGENTS, FEMALE; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 47749107576     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130802227724     Document Type: Review

References (40)

1. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-80
2. Wu O. Postmenopausal hormone replacement therapy and venous thromboembolism. Gender Med 2005;2(Suppl A):S18-27
3. Web page address: http://www.nhlbi.nih.gov/whi. Accessed on 7th December, 2007
4. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006;166:772-80
5. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
6. Rachon D, Zdrojewski T, Suchecka-Rachon K, et al. Knowledge and use of hormone replacement therapy among Polish women: estimates from a nationally representative study - HORTPOL 2002. Maturitas 2004;47:31-7
7. Ringa V, Ledesert B, Gueguen R, Schiele F, Breart G. Determinants of hormonal replacement therapy in recently postmenopausal women. Eur J Obstet Gynecol Reprod Biol 1992;45:193-200
8. Teede HJ, McGrath BP, Turner A, Majewski H. Effects of oral combined hormone replacement therapy on platelet aggregation in postmenopausal women. Clin Sci (Lond) 2001;100:207-13
9. Peverill RE, Teede HJ, Smolich JJ, et al. Effects of combined oral hormone replacement therapy on tissue factor pathway inhibitor and factor VII. Clin Sci (Lond) 2001;101:93-9
10. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997;17:3071-8
11. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619-25
12. Teede HJ, McGrath BP, Smolich JJ, et al. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol 2000;20:1404-9
13. Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy - results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000;84:961-7
14. Hoibraaten E, Os I, Seljeflot I, Andersen TO, Hofstad A, Sandset PM. The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease: results from the estrogen in women with atherosclerosis study. Thromb Res 2000;98:19-27
15. Cieplluch R, Czestochowska E. Influence of hormone replacement therapy (17 beta-OH estradiol and medroxyprogesterone acetate) on plasma concentration of prothrombin fragment F1+2 and thrombin-antithrombin III complex in postmenopausal woman. Acta Haematol Pol 1996;27:21-5
16. Ciepluch R, Czestochowska E. [Activity of endogenous anticoagulants (antithrombin III, protein C and protein S) in women after menopause treated with hormone replacement therapy (transdermal 17 beta-OH estradiol and oral medroxyprogesterone acetate)]. Ginekol Pol 1996;67:407-10
17. Ciepluch R, Czestochowska E. [Activity of plasminogen activator inhibitor (PAI-1) in plasma of women treated after menopause with hormone replacement therapy]. Pol Tyg Lek 1995;50:13-15
18. Oger E, Alhenc-Gelas M, Lacut K, et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003;23:1671-6
19. Post MS, Christella M, Thomassen LG, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003;23:1116-21
20. Rachon D, Suchecka-Rachon K, Hak L, Mysliwska J. Effects of intranasal 17beta-estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women. Menopause 2006;13:840-5
21. Lowe GD, Upton MN, Rumley A, McConnachie A, O'Reilly DS, Watt GC. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein - a cross-sectional population survey. Thromb Haemost 2001;86:550-6
22. Cano A, Van Baal WM. The mechanisms of thrombotic risk induced by hormone replacement therapy. Maturitas 2001;40:17-38
23. Perrot-Applanat M, Cohen-Solal K, Milgrom E, Finet M. Progesterone receptor expression in human saphenous veins. Circulation 1995;92:2975-83
24. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-5
25. Herkert O, Kuhl H, Sandow J, Busse R, Schini-Kerth VB. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor. Circulation 2001;104:2826-31
26. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002; 162:1182-9
27. Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003;89:493-8
28. Herrington DM, Vittinghoff E, Howard TD, et al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol 2002; 22:1012-17
29. Rosendaal FR, Vessey M, Rumley A, et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 2002;116:851-4
30. Wu O, Greer IA. Is screening for thrombophilia cost-effective? Curr Opin Hematol 2007;14:500-3
31. Straczek C, Oger E, Yon de Jonage-Canonico MB, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005;112:3495-500
32. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125:1-7
33. Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997;277:642-5
34. Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group. BMJ 1992;305:567-74
35. Grady D, Hulley SB, Furberg C. Venous thromboembolic events associated with hormone replacement therapy. JAMA 1997;278:477
36. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000;132:689-96
37. Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001;104:499-503
38. van der Vies J. Pharmacological studies with (7 alpha,17 alpha)- 17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD 14). Maturitas 1987;Suppl 1:15-24
39. Winkler UH, Altkemper R, Kwee B, Helmond FA, Coelingh Bennink HJ. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. Fertil Steril 2000;74:10-19
40. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97